Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biovaxys Technology Corp (BVAXF)

Biovaxys Technology Corp (BVAXF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0900 +42.89%
on 01/30/26
0.1900 -32.32%
on 01/16/26
-0.0429 (-25.01%)
since 01/02/26
3-Month
0.0900 +42.89%
on 01/30/26
0.2080 -38.17%
on 11/10/25
-0.0650 (-33.57%)
since 11/03/25
52-Week
0.0290 +343.45%
on 09/11/25
0.4490 -71.36%
on 02/25/25
-0.3314 (-72.04%)
since 02/03/25

Most Recent Stories

More News
Stocks in play: BioVaxys Technology Corp

Announced positive findings from a Phase 2 clinical study evaluating maveropepimut-S (MVP-S) in combination ...

BVAXF : 0.1286 (-0.92%)
Stocks in play: BioVaxys Technology Corp

Announces positive preliminary results from the PESCO study, an investigator-initiated, open-label, ...

BVAXF : 0.1286 (-0.92%)
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)

Study subject Remains in Complete Response for 3 YearsExceeds Expectations in Platinum-Resistant Ovarian Cancer Compared to Standard of Care Single-Agent ChemotherapyVancouver, British Columbia--(Newsfile...

BVAXF : 0.1286 (-0.92%)
BIOV.CN : 0.1750 (unch)
Stocks in play: BioVaxys Technology Corp

Announces highly promising results from a two-arm phase 1 clinical study of the safety and immunogenicity ...

BVAXF : 0.1286 (-0.92%)
BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer

Vancouver, British Columbia--(Newsfile Corp. - January 8, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company...

BVAXF : 0.1286 (-0.92%)
BIOV.CN : 0.1750 (unch)
Stocks in play: BioVaxys Technology Corp

Provides a summary of operating initiatives over the past year following the integration of the DPXâ„¢ ...

BVAXF : 0.1286 (-0.92%)
Stocks in play: BioVaxys Technology Corp

Announces positive results from a phase 1 clinical study of maveropepimut-S ("MVP-S") along with neoadjuvant ...

BVAXF : 0.1286 (-0.92%)
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company...

BVAXF : 0.1286 (-0.92%)
BIOV.CN : 0.1750 (unch)
Stocks in play: BioVaxys Technology Corp

Announces that Marianne Stanford, PhD, has joined BioVaxys as Scientific Advisor. Dr Stanford was Vice ...

BVAXF : 0.1286 (-0.92%)
Stocks in play: BioVaxys Technology Corp

Announces that, further to its news release dated November 14, 2025, it has issued 1,792,387 common ...

BVAXF : 0.1286 (-0.92%)

Key Turning Points

3rd Resistance Point 0.1541
2nd Resistance Point 0.1455
1st Resistance Point 0.1371
Last Price 0.1286
1st Support Level 0.1201
2nd Support Level 0.1115
3rd Support Level 0.1031

See More

52-Week High 0.4490
Fibonacci 61.8% 0.2886
Fibonacci 50% 0.2390
Fibonacci 38.2% 0.1894
Last Price 0.1286
52-Week Low 0.0290

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar